Subscribe To
TPST / TPST Stock: 7 Things to Know About Tempest Therapeutics
TPST News
By MarketBeat
October 17, 2023
The Secrets Behind a 4000% Biotech Stock Surge
Remarkably, the stock did not have fundamentally changing news. It did not rocket higher on breaking news that would typically be associated with the more_horizontal
By Market Watch
October 13, 2023
Tempest Therapeutics shares end wild week with 8% drop
Shares of Tempest Therapeutics Inc. TPST, -8.54% fell more than 8% Friday to conclude a dramatic week in which the stock clocked a one-day gain of nea more_horizontal
By Market Watch
October 12, 2023
Tempest Therapeutics shares head back to earth after 4,000% gain
Shares of microcap oncology company Tempest Therapeutics Inc. TPST, -55.06% dropped more than 50% Thursday as investors took a breath after the stock' more_horizontal
By Zacks Investment Research
October 12, 2023
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard- more_horizontal
By InvestorPlace
October 11, 2023
TPST Stock: 7 Things to Know About Tempest Therapeutics
Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ: TPST ). This little-known clinical-stage oncology company has gone from trading a more_horizontal
By InvestorPlace
October 11, 2023
Wall Street Warms Up to Tempest as TPST Stock Surges 1,500%
Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the cancer therapies more_horizontal
By Market Watch
October 11, 2023
Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise
Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigatio more_horizontal
By InvestorPlace
October 11, 2023
Why Is Tempest Therapeutics (TPST) Stock Up 325% Today?
Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. A more_horizontal